Join
today

Boliven PRO is more than just patent search

  • Build and save lists using the powerful Lists feature
  • Analyze and download your search results
  • Share patent search results with your clients

Patents »

US6923964: Active immunization of AScr for prion disorders

Share

Filing Information

Inventor(s) Dale B. Schenk ·
Assignee(s) Neuralab Limited ·
Attorney/Agent(s) Townsend and Townsend and Crew LLP ·
Primary Examiner Elizabeth Kemmerer ·
Assistant Examiner Christopher James Nichols ·
Application Number US9585817
Filing date 06/01/2000
Issue date 08/02/2005
Predicted expiration date 04/16/2020
Patent term adjustment 503
U.S. Classifications 424/185.1  · 514/12  · 514/4  · 514/2  ·
International Classifications --
Kind CodeB1
International Classifications 4241851 · 514 2 · 514 4 · 514 12 · 530300 · 530350 ·
Related U.S. Application DataThis application claims the benefit under 35 U.S.C. 119(e) of U.S. Application No. 60/137,010, filed Jun. 1, 1999, which is hereby incorporated herein in its entirety. This application is also a continuation-in-part of U.S. application Ser. No. 09/580,015, filed May 26, 2000, now abandoned, which is a continuation-in-part of U.S. application Ser. No. 09/322,289, filed May 28, 1999, which is a continuation in part of U.S. Ser. No. 09/201,430, filed Nov. 30, 1998, now U.S. Pat. No. 6,787,523 which claims the benefit under 35 U.S.C. 119(e) of U.S. Application No. 60/080,970, filed Apr. 7, 1998, and U.S. Application 60/067,740, filed Dec. 2, 1997.
10 Claims, 16 Drawings


Abstract

Disclosed are pharmaceutical compositions and methods for preventing or treating a number of amyloid diseases, including Alzheimer's disease, prion diseases, familial amyloid neuropathies and the like. The pharmaceutical compositions include immunologically reactive amounts of amyloid fibril components, particularly fibril-forming peptides or proteins. Also disclosed are therapeutic compositions and methods which use immune reagents that react with such fibril components.

Independent Claims | See all claims (10)

  1. 1. A method of treating a prior disorder associated with AScr in a mammalian subject suffering from the disorder, comprising administering to the subject a dosage of an agent effective to produce an immune response comprising antibodies against the agent and an adjuvant that augments the immune response to the agent, and thereby treating the disorder, wherein the agent is PrR or AScr.

References Cited

U.S. Patent Documents

Document NumberAssigneesInventorsIssue/Pub Date
US4666829 University of California Glenner et al. May 1987
US5004697 Univ. of CA Pardridge Apr 1991
US5057540 Cambridge Biotech Corporation Kensil et al. Oct 1991
US5187153 Scios Nova Inc. Cordell et al. Feb 1993
US5192753 MCGEER PATRICK L McGeer et al. Mar 1993
US5208036 Syntex (U.S.A.) Inc. Eppstein et al. May 1993
US5220013 Scios Nova Inc. Ponte et al. Jun 1993
US5231000 The McLean Hospital Majocha et al. Jul 1993
US5231170 AVERBACK PAUL Averback Jul 1993
US5270165 The Reagents of the University of California Van Nostrand et al. Dec 1993
US5387742 Scios Nova Inc. Cordell Feb 1995
US5434170 Andrulis Pharmaceuticals Corp. Andrulis, Jr. Jul 1995
US5441870 Athena Neurosciences, Inc. Seubert et al. Aug 1995
US5571499 Autoimmune, Inc. Hafler et al. Nov 1996
US5571500 Autoimmune, Inc. Hafler et al. Nov 1996
US5583112 Cambridge Biotech Corporation Kensil et al. Dec 1996
US5585100 Henry Jackson Foundation Mond et al. Dec 1996
US5593846 Athena Neurosciences Schenk et al. Jan 1997
US5605811 Athena Neurosciences, Inc. Seubert et al. Feb 1997
US5612486 Athena Neurosciences, Inc. McConlogue et al. Mar 1997
US5622701 Protein Design Labs, Inc. Berg Apr 1997
US5641473 AutoImmune, Inc. Hafler et al. Jun 1997
US5641474 AutoImmune, Inc. Hafler et al. Jun 1997
US5645820 AutoImmune, Inc. Hafler et al. Jul 1997
US5679348 Cedars-Sinai Medical Center Nesburn et al. Oct 1997
US5688651 RAMOT University Authority For Applied Research and Development Ltd. Solomon Nov 1997
US5733547 AutoImmune, Inc. Weiner et al. Mar 1998
US5736142 Cytel Corporation Sette et al. Apr 1998
US5744368 Research Foundation of State University of New York Goldgaber et al. Apr 1998
US5750349 Takeda Chemical Industries Ltd. Suzuki et al. May 1998
US5750361* The Regents of the University of California Prusiner et al. May 1998
US5753624 Milkhaus Laboratory, Inc. McMichael et al. May 1998
US5776468 SmithKline Beecham Biologicals (S.A.) Hauser et al. Jul 1998
US5780587 President and Fellows of Harvard College Potter Jul 1998
US5786180 Bayer Corporation Konig et al. Jul 1998
US5824322 CytRx Corporation Balasubramanian Oct 1998
US5837473 President and Fellows of Harvard College Maggio et al. Nov 1998
US5837672 Athena Neurosciences, Inc. Schenk et al. Nov 1998
US5846533* The Regents of the University of California Prusiner Dec 1998
US5849298 Autoimmune Inc. Weiner et al. Dec 1998
US5851996 Milkhaus Laboratory, Inc. Kline Dec 1998
US5854204 Praecis Pharmaceuticals, Inc. Findeis et al. Dec 1998
US5854996* Tektronix, Inc. Kline Dec 1998
US5869054 Autoimmune Inc. Weiner et al. Feb 1999
US5869093 Autoimmune Inc. Weiner et al. Feb 1999
US5877399 Johns Hopkins University Hsiao et al. Mar 1999
US5935927 The Picower Institute For Medical Research Vitek et al. Aug 1999
US5955079 Henry Jackson Foundation for the Advancement of Military Medicine Mond et al. Sep 1999
US5955317 Takeda Chemical Industries, Ltd. Suzuki et al. Sep 1999
US5958883 Board of Regents of the University of Washington Office of Technology Snow Sep 1999
US5989566 American Cyanamid Company Cobb et al. Nov 1999
US6057367 Duke University Stamler et al. May 2000
US6114133 Elan Pharmaceuticals, Inc. Seubert et al. Sep 2000
US6150091 Baylor College of Medicine Pandolfo et al. Nov 2000
US6262335 Johns Hopkins University Hsiao et al. Jul 2001
US6284221 Elan Pharmaceuticals, Inc. Schenk et al. Sep 2001
US6294171 Milkhaus Laboratory, Inc. McMichael Sep 2001
US6417178 University of Pittsburgh Klunk et al. Jul 2002
US20010018053 McMichael Aug 2001
US20010021769* Prusiner Sep 2001
US20020009445 Du et al. Jan 2002
US20020077288 New York University Frangione Jun 2002
US20020102261 Boston Biomedical Research Institute Raso Aug 2002
US20020132268* Chang et al. Sep 2002
US20020136718 Boston Biomedical Research Institute Raso Sep 2002
US20020162129 Lannfeit Oct 2002
US20020168377* Schaetzl Nov 2002
US20020197258* Ghanbari et al. Dec 2002

Foreign Patent Documents

Document NumberAssigneesInventorsIssue/Pub Date
EP451700Oct 1991
EP276723Dec 1993
EP613007Aug 1994
EP666080Aug 1995
EP359783Nov 1995
EP683234Nov 1995
EP440619Jan 1996
EP526511May 1997
EP782859Jul 1997
EP783104Jul 1997
EP594607Aug 1997
EP845270Jun 1998
EP863211Sep 1998
EP868918Oct 1998
EP652962Dec 1998
EP911036Apr 1999
EP561087Aug 1999
EP639081Nov 1999
EP506785Mar 2000
EP1172378Dodel, Richard, Dr.Jan 2002
GB2220211RIBI IMMUNOCHEM RESEARCH INCJan 1990
GB2335192EXONHIT THERAPEUTICS SASep 1999
WO198810120Dec 1988
WO198901343Feb 1989
WO198903687May 1989
WO198906242Jul 1989
WO198906689Jul 1989
WO199012870Nov 1990
WO199012871Nov 1990
WO199108760Jun 1991
WO199112816Sep 1991
WO199116819Nov 1991
WO199116819*Nov 1991
WO199119810Dec 1991
WO199206187Apr 1992
WO199206708Apr 1992
WO199213069Aug 1992
WO199302189Feb 1993
WO199304194Mar 1993
WO199314200Jul 1993
WO199315760Aug 1993
WO199316724Sep 1993
WO199321950Nov 1993
WO199401772Jan 1994
WO199403615Feb 1994
WO199428412Dec 1994
WO199504151Feb 1995
WO199505853Mar 1995
WO199511008Apr 1995
WO199511311Apr 1995
WO199511994May 1995
WO199512815May 1995
WO199531996Nov 1995
WO199618900Jun 1996
WO199625435Aug 1996
WO199628471Sep 1996
WO199639176Dec 1996
WO199710505*Apr 1997
WO199717613May 1997
WO199721728Jun 1997
WO199807850Feb 1998
WO199844955Oct 1998
WO199900150Jan 1999
WO199906066Feb 1999
WO199906545*Feb 1999
WO199927911Jun 1999
WO199927944Jun 1999
WO199927949Jun 1999
WO199906545Nov 1999
WO199958564NORSK HYDRO ASANov 1999
WO199960021YEDA RESEARCH AND DEVELOPMENT CO. LTD.Nov 1999
WO199960024THE UNIVERSITY OF TENNESSEE RESEARCH CORPORATIONNov 1999
WO200162284PHARMEXA A/SMar 2000
WO200043039DURING, Matthew, JohnJul 2000
WO200043049PHARMACIA & UPJOHN COMPANYJul 2000
WO20PCT0072870Dec 2000
WO20PCT0072876Dec 2000
WO20PCT0072876Dec 2000
WO20PCT0072880Dec 2000
WO20PCT0072880Dec 2000
WO200077178BOSTON BIOMEDICAL RESEARCH INSTITUTEDec 2000
WO200203911Lars LANNFELTApr 2001
WO200139796NEUROCHEM INC.Jun 2001
WO200142306MINDSET BIOPHARMACEUTICALS (USA), INC.Jun 2001
WO200162801WASHINGTON UNIVERSITYAug 2001
WO200177167Oct 2001
WO200190182NEW YORK UNIVERSITYNov 2001
WO200234777CHIESI FARMACEUTICI S.P.A.May 2002
WO200234878YEDA RESEARCH AND DEVELOPMENT CO. LTD.May 2002
* cited by examiner

Other Publications

Jen et al. (1997) Preparation and Purification of antisera against different regions or isoforms of beta-amyloid precursor protein. Brain Research Protocols 2:23-30.*
Jobling et al, Mol. Microbiol., 1991, 5(7):1755-67.*
Skolnick and Fetrow (2000) From Genes to Protein Strucuture and Function: Novel Applications of Compuational Approaches in the Genomic Era. Trends in Biotech 18(1); 34-39.*
Chen et al., Progress in Br. Res., 1998, 117:327-34.*
Kovács et al. (2002) “Mutations of the Prion Protein Gene: Phenotypic Spectrum.” J. Neurol. 249: 1567-1582.*
Weissman & Aguzzi (1997) “Bovine Spongiform encephalopathy and early onset variant Creutzfeldt-Jakob disease.” Current Opinion in Neurobiology 7: 695-700.*
Sigurdsson et al. (2003) “Anti-prion antibodies for prophylaxis following prion exposure in mice.” Neuroscience Letters 336: 185 187.*
Sigurdsson et al. (Jul. 2002) “Immunization Delays the Onset of Prion Disease in Mice.” American Journal of Pathology 161(1) 13-17.*
Tal et al. (2003) “Complete Freund's Adjuvant Immunization Prolongs Survival in Experimental Prion Disease in Mice.” Journal of Neuroscience Research 71: 286-290.*
Wisniewski et al. (2002) “Therapeutics in Alzheimer's and Prion Diseases.” Biochemical Society Transactions 30(4): 574-578.*
Diomede et al. (1996) “Activation effects of a prion protein fragment [PrP-(106-126)] on human leucocytes.” Biochem. J. 320: 563-570.*
Goldfarb & Brown (1995) “The Transmissible Spongiform Encephalopathies.” Annu. Rev. Med. 46: 57-65.*
Aguzzi & Weissman (Oct. 23, 1997) “Prion research: the next frontiers.” Nature 398: 795-798.*
Prusiner et al. (Nov. 1993) “Ablation of the prion protein (PrP) in mice prevents scrapie and facilitates production of anti-PrP antibodies.” PNAS 90: 10608-10612.*
Hsiao (1997) “From prion diseases to Alzheimer's disease.” J Neural Transm Suppl. 49: 135-144.*
Harmeyer et al. (Apr. 1998) “Synthetic peptide vaccines yield monoclonal antibodies to cellular and pathological prion proteins of ruminants.” Journal of General Virology 79(4): 937-945.*
Goldsby et al. (2002) Kuby Immunology Chapter 18 “Vaccines” (pp. 449-465).*
Brown et al. (Jun. 1997) “PrP and b-Amyloid Fragments Activate Different Neurotoxic Mechanisms in Cultured Mouse Cells.” European Journal of Neuroscience 9(6): 1162-1169.*
Jobling & Holmes (1991) “Analysis of structure and function of the B Subunit of cholera toxin by the use of site-directed mutagenesis.” Molecular Microbiology 5(7): 1755-67.*
Elan Press Releases (Mar. 1, 2001 and Jan. 18, 2002).*
Skolnick & Fetrow (2000) “From genes to protein structure and function: novel applications of computational approaches in the genomic era.” Trends in Biotech. 18(1): 34-39.*
Andersen et al., “Do nonsteroidal anti-inflammatory drugs decrease the risk for Alzheimer's disease?,” Neurology, 45:1441-1445 (1995).
Associated Press, “Immune cells may promote Alzehimer's, a study finds,” The Boston Globe (Apr. 13, 1995).
Bauer et al., “Interleukin-6 and α-2-macroglobulin indicate an acute-phase state in Alzheimer's disease cortices,” FEBS Letters, 285(1):111-114 (1991).
Bard et al., “Peripherally administered antibodies against amyloid β-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease,” Nature Medicine, 6(8):916-919 (2000).
Blass, John P., “Immunologic Treatment of Alzheimer's Disease,” New England J. Medicine, 341(22):1694 (1999).
Bodmer et al., “Transforming Growth Factor-Beta Bound to Soluble Derivatives of the Beta Amyloid Precursor Protein of Alzheimer's Disease,” Biochem. Biophys. Res. Comm., 171(2):890-897 (1990).
Borchelt et al., “Accelerated Amyloid Deposition in the Brains of Transgenic Mice Coexpressing Mutant Presenilin 1 and Amyloid Precursor Proteins,” Neuron, 19: 939-945 (1997).
Boris-Lawrie et al., “Recent advances in retrovirus vector technology,” Cur. Opin. Genet. Develop., 3: 102-109 (1993).
Brice et al., “Absense of the amyloid precursor protein gene mutation (APP717 : Val->lle) in 85 cases of early onset Alzheimer's disease,” J. Neurology, Neurosurg. Psychiatry, 56:112-115 (1993).
Chao et al., “Transforming Growth Factor-β Protects human Neurons Against β-Amyloid-Induced Injury,” Soc. Neurosci. Abstracts, 19:513.7 (1993).
Duff et al., “Mouse model made,” Nature, 373: 476-477 (1995).
Elizan et al., “Antineurofilament antibodies in a postencephalitic and idiopathic parkinson'disease,” J. Neurol. Sciences, 59:341-347 (1983).
Felsenstein et al., “Processing of the β-amyloid precursor protein carrying the familial, Dutch-type, and a novel recombinant C-terminal mutation,” Neuroscience Letters, 152:185-189 (1993).
Finch et al., “Evolutionary Perspectives on Amyloid and Inflammatory Features of Alzheimer Disease,” Neurobiology of Aging, 17(5):809-815 (1996).
Fisher et al., “Expression of the amyloid precursor protein gene in mouse oocytes and embryos,” PNAS, 88:1779-1782 (1991).
Flanders et al., “Altered expression of transforming growth factor-β in Alzheimer's disease,” Neurology, 45:1561-1569 (1995).
Games et al., “Alzheimer-type neuropathology in transgenic mice overexpressing V717F β-amyloid precursor protein,” Nature, 373(6514): 523-527 (1995).
Gandy et al., “Amyloidogenesis in Alzheimer's disease: some possible therapeutic opportunities,” TiPS, 13:108-113 (1992).
Gaskin et al., “Human antibodies reactive with beta-amyloid protein in Alzheimer's disease,” J. Exp. Med., 117:1181-1186 1993).
Glenn et al., “Skin immunization made possible by cholera toxin,” Nature, 391: 851 (1998).
Glenner et al., “Alzheimer's Disease: Initial Report of the Purification and Characterization of a Novel Cerebrovascular Amyloid Protein,” Biochemical and Biophysical Research Communications, 120(3): 885-890 (1994).
Glenner et al., “Alzheimer's Disease and Downs Syndrome: Sharing of A Unique Cerebrovascular Amyloid Fibril Protein,” Biochemical and Biophysical Research Communications, 122(3): 1131-1132 (1984).
Goate et al., “Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease,” Nature, 349:704-706 (1991).
Gozes et al., “Neuroprotective strategy for Alzheimer disease: Intranasal administration of a fatty neuropeptide,” PNAS, 93:427-432 (1996).
Gravina et al., “Amyloid β Protein (Aβ) in Alzheimer's Diseaase,” J. Biol. Chem., 270(13):7013-7016 (1995).
Gupta et al., “Differences in the immunogenicity of native and formalized cross reacting material (CRM197) of diptheria toxin in mice and guinea pigs and their implications on the development and control of diphtheria vaccine based on CRMs,” Vaccine, 15(12/13): 1341-1343 (1997).
Haga et al., “Synthetic Alzheimer amyloid β/A4 peptides enhance production of complement C3 component by cultured microglial cells,” Brain Research, 601:88-94 (1993).
Hanes et al., “New advances in microsphere-based single-dose vaccines,” Advanced Drug Delivery Reviews, 28:97-119 (1997).
Hardy, “Amyloid, the presenilins and Alzheimer's disease,” TINS, 20(4): 154-159 (1997).
Hardy, John, “New Insights into the Genetics of Alzheimer's Disease,” Annals of Med., 28:255-258 (1996).
Harrington et al., “Characterisation of an epitope specific to the neuron-specific isoform of human enolase recognised by a monoclonal antibody raised against a synthetic peptide corresponding to the C-terminus of β / A4-protein,” Biochimica Biophysica Acta, 1158:120-128 (1993).
Helmuth, L., “Further Progress on a β-Amyloid Vaccine,” Science, 289:375 (2000).
Hsiao et al., “Correlative Memory Deficits, AβElevation, and Amyloid Plaques in Transgenic Mice,” Science, 274: 99-102 (1996).
Huberman et al., “Correlation of cytokine secretion by mononuclear cells of Alzheimer's patients and their disease stage,” J. Neuroimmunology, 52:147-152 (1994).
Hyman et al., “Molecular Epidemiology of Alzheimer's Disease,” N. E. J. Medicine, 333(19):1283-1284 (1995).
Itagaki et al., “Relationship of microglia and astrocytes to amyloid deposits of Alzheimer's disease,” J. Neuroimmunology, 24:173-182 (1989).
Iwatsubo et al., “Visualization of Aβ42(43) and Aβ40 in Senile Plaques with End-Specific Aβ Monoclonals: Evidence That an Initially Deposited Species is Aβ42(43),” Neuron, 13:45-53 (1994).
Jansen et al., “Immunotoxins: Hybrid Molecules Combining High Specificity and Potent Cytotoxicity,” Immun. Rev., 62: 185-216 (1982).
Kalaria, R. N., “Serum amyloid P and related molecules associated with the acute-phase response in Alzheimer's disease,” Res. Immunology, 143:637-641 (1992).
Katzav-Gozansky et al., “Effect of monoclonal antibodies in preventing carboxypeptidase A aggregation,” Biotechnol. Appl. Biochem., 23:227-230 (1996).
Kawabata et al., “Amyloid plaques, neurofibrillary tangles and neuronal loss in brains of transgenic mice overexpressing a C-terminal fragment of human amyloid precursor protein,” Nature, 354:476-478 (1991).
Konig et al., “Development and Characterization of a Monoclonal Antibody 369.2B Specific for the Carboxyl-Terminus of the βA4 Peptide,” Annals of NY Acad. Sci., 777:344-355 (1996).
Lampert-Etchells et al., “Regional Localization of Cells Containing Complement C1q and C4 mRNAs in the Frontal Cortex During Alzheimer's Disease,” Neurodegeneration, 2:111-121 (1993).
Langer, “New Methods of Drug Delivery,” Science, 249: 1527-1532 (1990).
Lannfelt et al., “Alzheimer's disease: molecular genetics and transgenic animal models,” Behavioural Brain Res., 57:207-213 (1993).
Lemere et al., “Mucosal Administration of Aβ Peptide Decreases Cerebral Amyloid Burden in Pd-App Transgenic Mice,” Society for Neuroscience Abstracts, vol. 25, part 1, Abstract 519.6, 29th Annual Meeting, Oct. 23-28, 1999.
Livingston et al., “The Hepatitis B Virus-Specific CTL Responses Induced in Humans by Lipopeptide Vaccination Are Comparable to Those Elicited by Acute Viral Infection,” J. Immunol., 159: 1383-1392 (1997).
Lopez et al., “Serum auto-antibodies in Alzheimer's disease,” Acta. Neurol. Scand., 84:441-444 (1991).
McGee et al., “The encapsulation of a model protein in poly (D, L lactide-co-glycolide) microparticles of various sizes: an evaluation of process reproducibility,” J. Micro. Encap., 14(2): 197-210 (1997).
Meda et al., “Activation of microglial cells by β-amyloid protein and interferon-γ,” Nature, 374:647-650 (1995).
Miller et al., “Antigen-driven Bystander Suppression after Oral Administration of Antigens,” J. Exp. Med., 174:791-798 (1991).
Murphy et al., “Development of a Monoclonal Antibody Specific for the COOH-Terminal of β-Amyloid 1-42 and Its Immunohistochemical Reactivity in Alzheimer's Disease and Related Disorders,” Am. J. Pathology, 144(5):1082-1088 (1994).
Nathanson et al., “Bovine Spongiform Encephalopathy (BSE): Causes and Consequences of a Common Source Epidemic,” Am. J. Epidemiol., 145(11): 959-969 (Jun. 1, 1997).
New York Times National, “Anti-Inflammatory Drugs May Impede Alzheimer's,” (Feb. 20, 1994).
Selkoe, Dennis J., “The Molecular pathology of Alzheimer's Disease,” Neuron, 6:487-498 (1991).
Selkoe, Dennis J., “Alzheimer's Disease: Genotypes, Phenotype, and Treatments,” Science, 275:630-631 (1997).
Seubert et al., “Isolation and quantification of soluble Alzheimer's β-peptide from biological fluids,” Nature, 359: 325-327 (1992).
Shiosaka, S., “Attempts to make models for Alzheimer's disease,” Neuroscience Res., 13:237-255 (1992).
Smits et al., “Prion Protein and Scrapie Susceptibility,” Vet. Quart., 19(3): 101-105 (1997).
Solomon et al., “Disaggregation of Alzheimer β-amyloid by site-directed mAb,” PNAS, 94:4109-4112 (1997).
Solomon et al., “Monoclonal antibodies inhibit in vitro fibrillar aggregation of the Alzheimer β-amyloid peptide,” PNAS, 93:452-455 (1996).
Solomon et al., “Inhibitory effect of monoclonal antibodies on Alzheimer's β-amyloid peptide aggregation,” Int. J. Exp. Clin. Invest., 3:130-133 (1996).
Cameron, E., “Recent Advances in Transgenic Technology,” Molecular Biotechnology, 7:253-265 (1997).
Felsenstein et al., “Transgenic Rat and In-Vitro Studies of B-Amyloid Protein Precursor Processing;” Alzheimer's and Parkinson's Diseases, Hanin et al. Ed., pp 401-409, Plenum Press, New York, (1995).
Niemann, H., “Transgenic farm animals get off the ground;” Transgenic Research 7:73-75 (1998).
Sigmund, C., “Viewpoint: Are Studies in Genetically Altered Mice Out of Control,” Arterioscler Thromb Vasc Biol., 20:1425-1429 (2000).
Barrow et al., “Solution Conformations and aggregational Properties of Synthetic Amyloid Beta-Peptides of Alzheimer's Disease. Analysis of Circular Dichroism Spectra” J. Mol. Biol., 225(4): 1075-1093 (1992).
Beasley, “Alzheimer's traced to proteins caused by aging,” Reuters, Apr. 20, 2001 7:56 PM ET.
Bercovici et al., “Chronic Intravenous Injections of Antigen Induce and Maintain Tolerance in T Cell Receptor-Transgenic Mice,” Eur. J. Immunol. 29:345-354 (1999).
Bickel et al., “Site Protected, Cationized Monoclonal Antibody Against Beta Amyloid as a Potential Diagnostic Imaging Technique for Alzheimer's Diseases,” Soc. for Neuroscience Abstracts 18:764 (1992).
Caputo et al., “Therapeutic approaches targeted at the amyloid proteins in Alzheimer's disease,” Clin. Neuropharm., 15:414A-414B (1992).
Center for Biologics Evaluation and Research, U.S. Food and Drug Administration, Thimerosal in Vaccines (Mercury in Plasma-Derived Products), web site contents found at : http://www.fda.gov/cber/vaccine/thimerosal.htm, last updated May 16, 2002.
Chapman, Paul F., “Model behavior,” Nature, 408:915-916 (2000).
Chemical Abstract database, Abstract of “Injection of Newborn Mice with Seven Chemical Adjuvants to Help Determine Their Safety in Use in Biologicals,” Chemical Abstract database. (Publication date unknown.).
Chen et al. “An Antibody to β Amyloid Precursor Protein Inhibits Cell-substratum Adhesion In Many Mammalian Cell Types,” Neuroscience Letters 125:223-226 (1991).
Chung et al. “Uptake, Degradation, and Release of Fibrillar and Soluble Forms of Alzheimer's Amyloid β-Peptide by Microglial Cells,” J. Biol. Chem., 274(45):32301-32308 (1999).
Coloma et al., “Transport Across the Primate Blood-Brain Barrier of a Genetically Engineered Chimeric Monoclonal Antibody to the Human Insulin Receptor,” Pharm. Res., 17:266-274 (2000).
Cordell, B., “β-Amyloid formation as a potential therapeutic target for Alzheimer's disease,” Ann. Rev. Pharmacol. Toxicol., 34:69-89 (1994).
Costa et al., “Immunoassay for transthyretin variants associated with amyloid neuropathy,” Scand. J. Immunol., 38:177-182 (1993).
Daly, et al., “Detection of the membrane-retained carboxy-terminal tail containing polypeptides of the amyloid precursor protein in tissue from Alzheimer's Disease brain,” Life Sci., 63:2121-2131 91998).
DeMattos et al., “Peripheral Anti Aβ Antibody Alters CNS And Plasma Aβ Clearance and Decreases Brain Aβ Burden in a Mouse Model of Alzheimer's Disease,” Proc. Natl. Acad. Sci. USA, 10.1073/pnas. 151261398 (2001).
Dumery et al., “β-Amyloid protein aggregation: its implication in the physiopathology of Alzheimer's disease,” Pathol. Biol., 49:72-85 (2001).
Elan, “Elan and AHP Provide an Update on the Phase 2A Clinical Trial of AN-1792,” Press Release. (Jan. 28, 2002).
Elan, “Elan and Wyeth Provide Update on Status of Alzheimer's Collaboration,” Press Release (Mar. 1, 2002).
Esiri, “Is an effective immune intervention for Alzheimer's disease in prospect?,” Trends in Pharm. Sci., 22:2-3 (2001).
Frenkel et al., “Generation of auto-antibodies towards Alzheimer's disease vaccination,” Vaccine, 19:2615-2619 (2001).
Frenkel et al., “High affinity binding of monoclonal antibodies to the sequential epitope EFRH of β-amyloid peptide is essential for modulation of fibrillar aggregation,” J. of Neuroimmunology, 95:136-142 (1999).
Frenkel et al., “Immunization against Alzheimer's β-amyloid plaques via EFRH phage administration,” PNAS USA, 97:11455-11459 (2000).
Frenkel et al., “N-terminal EFRH sequence of Alzheimer's β-amyloid peptide represents the epitope of its anti-aggregating antibodies,” J. of Neuroimmunology, 88:85-90 (1998).
Frenkel et al., “Modulation of Alzheimer's β-amyloid neurotoxicity by site-directed single chain antibody,” J. of Neuroimmunology, 106:23-31 (2000).
Friedland et al., “Development of an anti-Aβ monoclonal antibody for in vivo imaging of amyloid angiopathy in Alzheimer's disease,” Mol. Neurology, 9:107-113 (1994).
Friedland, et al., “Neuroimaging of Vessel Amyloid in Alzheimer's Disease,” in Cerebrovascular Pathology in Alzheimer's Disease, eds. de la Torre and Hachinski, New York Academy of Sciences, New York, New York (1997).
Games et al., “Prevention and Reduction of AD-type Pathology in PDAPP Mice Immunized with Aβ1-42,” Annals of the New York Academy of Science 920:274-84 (2000).
Gardella et al., “Intact Alzheimer amyloid precursor protein (APP) is present in platelet membranes and is encoded by platelet mRNA,” Biochem. Biophys. Res. Comm., 173:1292-1298 (1990).
Geddes, “N-terminus truncated β-amyloid peptides and C-terminus truncated secreted forms of amyloid precursor protein: distinct roles in the pathogenesis of Alzheimer's disease,” Neurobiology of Aging, 20:75-79 (1999).
Giulian, et al., “The HHQK Domain of b-Amyloid Provides a Structural Basis for the Immunopathology of Alzheimer's Disease,” Journal of Biological Chem., 273:29719-29726 (1998).
Gonzales-Fernandez et al., “Low antigen dose favors selection of somatic mutants with hallmarks of antibody affinity maturation,” Immunology, 93:149-153 (1998).
Gortner, Outlines of Biochemistry, pp. 322-323, John Wiley & Sons, Inc., New York (1949).
Grubeck-Loebenstein, et al., “Immunization with β-amyloid: could T-cell activation have a harmful effect?”, TINS, 23:114 (2000).
Haass et al. “Amyloid beta-peptide is produced by cultured cells during normal metabolism,” Nature, 359(6393):322-5 (1992).
Harigaya, et al., “Modified amyloid β protein ending at 42 or 40 with different solubility accumulates in the brain of Alzheimer's disease,” Biochem. Biophys. Res. Comm., 211:1015-1022 (1995).
Hazama, et al., “Intranasal Immunization Against Herpes Simplex Virus Infection by Using a Recombinant Glycoprotein D Fused With Immunomodulating Proteins, the B Subunit of Escherichia coli Heat-Labile Enterotoxin and Interleukin-2”, Immunology, vol. 78: 643-649 (1993).
Hilbich et al., :Human and rodent sequence analogs of Alzheimer's amyloid βA4 share similar properties and can be solubilized in buffers of pH 7.4, Eur. J. Biochem., 201:61-69 (1991).
Ikeda, et al., “Immunogold labeling of cerebrovascular and neuritic plaque fibrils in Alzheimer's disease with an anti-β protein monoclonal antibody,” Lab. Invest., 57:446-449 (1987).
Jen, et al., “Preparation and purification of antisera against different regions or isoforms of b-amyloid precursor protein,” Brain Research Protocols, 2:23-30 (1997).
Joachim et al., “Antibodies to Non-beta Regions of the Beta-amyloid Precursor Protein Detect a Subset of Senile Plaques,” Am. J. of Pathology 138:373-384 (1991).
Kida, et al., “Early amyloid-β deposits show different immunoreactivity to the amino- and carboxy-terminal regions of b-peptide in Alzheimer's disease and Down's syndrome brain,” Neuroscience Letters, 193:105-108 (1995).
Lansbury, Peter T., “Inhibition of amyloid formation: a strategy to delay the onset of Alzheimer's disease,” Curr. Ops. in Chemical Biology, 1:260-267 (1997).
Lemere, et al., “Nasal Aβ treatment induces anti-Aβ antibody production and decreases cerebral amyloid burden in PD-APP mice,” Annals of the NY Acad. Sci., 920:328-331 (2000).
Majocha et al., “Development of a Monoclonal Antibody Specific for β/A4 Amyloid in Alzheimer's Disease Brain for Application to In Vitro Imaging of Amyloid Angiopathy,” The J. of Nuclear Med., 33:2184-2189 (1992).
Mak, et al., “Polyclonals to b-amyloid (1-42) identify most plaque and vascular deposits in Alzheimer cortex, but not striatum,” Brain Research, 667:138-142 (1994).
Mann, et al., “Amyloid β Protein (Aβ) deposition in chromosome 14-linked Alzheimer's disease: Predominance of Aβ42(43),” Annals of Neurology, 40:149-156 (1996).
Mann, et al., “The extent of amyloid deposition in brain in patients with Down's syndrome does not depend upon the apoliprotein E genotype,” Neuroscience Letters, 196:105-108 (1995).
Masters et al., “Amyloid Plaque core protein in Alzheimer Disease and Down Syndrome,” Proc. Natl. Acad. Sci. USA, 82:4245-4249 (1985).
McGeer, et al., “Immunohistochemical localization of beta-amyloid precursor protein sequences in Alzheimer and normal brain tissue by light and electron microscopy,” J. of Neuroscience Res., 31:428-442 (1992).
McNeal et al., “Stimulation of local immunity and protection in mice by intramuscular immunization with triple- or double-layered rotavirus particles and QS-21,” Virology, 243:158-166 (1998).
Mena, et al., “Monitoring pathological assembly of tau and β-amyloid proteins in Alzheimer's disease,” Acta Neuropathol., 89:50-56 (1995).
Mori et al., “Mass Spectrometry of Purified Amyloid β Protein in Alzheimer's Disease,” J. Biol. Chem., 267(24):17082-17088 (1992).
Morris, et al., “The Consortium to Establish a registry for Alzheimer's Disease (CERAD),” Neurology, 39:1159-65 (1989).
Nakamura, et al., “Carboxyl end-specific monoclonal antibodies to amyloid β protein (Aβ) subtypes (Aβ40 and Aβ42(43)) differentiate Ab in senile plaques and amyloid angiopathy in brains of aged cynomolgus monkeys,” Neuroscience Letters, 201:151-154 (1995).
Nakayama et al., “Histopathological studies of senile plaques and cerebral amyloidosis in cynomolgus monkeys,” J. of Med. Primatology, 27:244-252 (1998).
Newcombe and Cohen, “Solubility characteristics of isolated amyloid fibrils,” Biochim. Biophys. Acta, 104:480-486 (1965).
Pardridge et al., “Chimeric peptides as a vehicle for peptide pharmaceutical delivery through the blood-brain barrier,” Biochem. Biophys. Res. Comm., 146:307-313 (1987).
Peterson, et al., “Recombinant Antibodies: Alternative Strategies for Developing and Manipulating Murine-Derived Monoclonal Antibodies,” Laboratory Animal Science, 46(1):8-14 (1996).
Philippe, et al. “Generation of a monoclonal antibody to the carboxy-terminal domain of tau by immunization with the amino-terminal domain of the amyloid precursor protein,” J. of Neuroscience Res., 46:709-719 (1996).
Rudinger, “Characteristics of the Amino Acids as Components of a Peptide Hormone Sequence,” in Peptide Hormones, J.A. Parson, ed. University Park Press, Baltimore, pp. 1-7 (1976).
Saito et al., “Vector-mediated delivery of 125I-labeled β-amyloid peptide Ab1-40 through the blood-brain barrier and binding to Alzheimer disease amyloid of the Aβ1-40 vector complex,” PNAS USA, 92:10227-10231 (1995).
Sasaki et al., “Human choroid plexus is an uniquely involved area of the brain in amyloidosis: a histochemical, immunohistochemical and ultrastructural study,” Brain Res., 755:193-201 (1997).
Schenk, et al., “β-peptide immunization,” Arch. Nuerol., 57:934-936 (2000).
St. George-Hyslop, Peter H. and David A. Westaway, :Antibody clears senile plaques, Nature, 40:116-117 (1999).
Szendrei, et al., “The effects of aspartic acid-bond isomerization on in vitro properties of the amyloid β-peptide as modeled with N-terminal decapeptide fragments,” Int. J. Peptide Protein Res., 47:289-296 (1996).
Thorsett, E.D. and L.H. Latimer, “Therapeutic approaches to Alzheimer's disease,” Curr. Op. in Chem. Biology, 4:377-382 (2000).
Tjernberg et al., “Arrest of β-amyloid fibril formation by a pentapeptide ligand,” Journal of Biological Chemistry, 271:8545-8548 (1996).
Weiner et al., “Nasal administration of amyloid-β peptide decreases cerebral amyloid burden in a mouse model of Alzheimer's disease,” Annals of Neurology, 48:567-579 (2000).
Wong et al., “Neuritic Plaques and Cerebrovascular Amyloid in Alzheimer Disease are Antigenically Related,” PNAS USA, 82:8729-8732 (1985).
Wu, et al., “Drug targeting of a peptide radiopharmaceutical through the primate blood-brain barrier in vivo with a monoclonal antibody to the human insulin receptor,” J. Clin. Invest., 100:1804-1812 (1997).
Yamaguchi et al., Diffuse plaques associated with astroglial amyloid β protein, possibly showing a disappearing stage of senile plaques, Acta Neuropathol., 95:217-222 (1998).
Younkin, “Amyloid β vaccination: reduced plaques and improved cognition,” Nature Medicine, 7:18-19 (2001).
Parecse et al., “Microglial cells influence aggregates of the Alzheimer's disease amyloid beta-protein via a scavenger receptor,” Neuron, 17:553-565 (Sep. 1996).
Paul et al., “Transdermal immunization with large proteins by means of ultradeformable drug carriers”, Eur. J. Immunol., 25: 3521-3524 (1995).
Prieels et al., “Synergistic adjuvants for vaccines,” Chemical Abstracts, 120(8): p. 652, col. 1, abstract 86406t (1994).
Quon et al., “Formation of β-Amyloid protein deposits in brains of transgenic mice,” Nature, 352:239-241 (1991).
Raso, “Immunotherapy of Alzheimer's Disease,” Immunotherapy Weekly, Abstract (Apr. 12, 1998).
Rogers et al., “Complement activation by β-amyloid in Alzheimer Disease,” PNAS, 89:1-5 (1992).
Rossor et al., “Alzheimer's Disease Families with Amyloid Precursor Protein Mutations,” Annals of New York Academy of Sciences, 695:198-202 (1993).
Saido et al., “Spatial Resolution of Fodrin Proteolysis in Postischemic Brain,” J. Biol. Chem., 268:(33):25239-25243 (1993).
Saido et al., “Spatial Resolution of the Primary β-Amyloidogenic Process Induced in Postischemic Hippocampus,” J. Biol. Chem., 269(21):15253-15257 (1994).
Solomon, A., “Pro-Rx (Protein Therapeutics),” University of Tennessee Medical Center (publication date unknown).
U.S. Appl. No. 09/724,842, filed Nov. 28, 2000, Chalifour et al.
Chen, et al. A learning deficit related to age and beta-amyloid plaques in a mouse model of Alzheimer's disease. Nature. 408(6815):975-9 (2000).
Du, et al. Reduced levels of amyloid beta-peptide antibody in Alzheimer disease. Nuerology 57(5):801-5 (2001).
Janus, et al., “Preparation and purification of antisera against different regions or isoforms of b-amyloid precursor protein,” Brain Research Protocols, 2:23-30 (1997).
Mattson, MP. Cellular actions of beta-amyloid precursor protein and its soluble and fibrillogenic derivatives. Physiol Rev. 77(4):1081-132 (1997).
Merluzzi, et al. Humanized antibodies as potential drugs fro therapeutic use. Adv Clin path. 4(2):77-85 (2000).
Morgan, et al. A beta peptide vaccination prevents memory loss in an animal model of Alzheimer's disease. Nature. 408(6815):982-5 (2000).
Schenk, et al. Immunotherapy with beta-amyloid for Alzheimer's disease: a new frontier. DNA Cell Biol. 20(11):679-81 (2001).
Selkoe, DJ. The cell biology of beta-amyloid precursor protein and presenilin in Alzheimer's disease. Trends Cell Biol. 8(11):447-53 (1998).
Sigurdsson, et al. In vivo reversal of amyloid-beta lesions in rat brain. J Neuropathol Exp Neurol. 59(1):11-17 (2000).
Sinha, et al. Recent advances in the understanding of the processing of APP to beta amyloid peptide. Ann N Y Acad Sci. 920:206-8 (2000).
Small, et al. Alzheimer's disease and Abeta toxicity: from top to bottom. Nat Rev Neurosci. 2(8):595-8 (2001).
Soto, et al. Beta sheet breaker peptides inhibit fibrillogenesis in a rat brain model of amyloidosis: implications for Alzheimer's therapy. Nat Med. 4(7):822-6 (1998).
Vehmas, et al. beta-Amyloid peptide vaccination results in marked changes in serum and brain Abeta levels in Appswe/PS1 DeltaE9 mice, as detected by SELDI-TOF-based ProteinChip® technology. DNA Cell Biol. (11):713 21 (2001).
Chen et al., “Neurodegenerative Alzheimer-like pathology in PDAPP 717V→F transgenic mice,” Progress in Brain Research, Van Leeuwen et al. Eds, 117:327-337 (1998).
Conway et al., “Acceleration of oligomerization, not fibrillization, is a shared property of both α-synuclein mutations linked to early-onset Parkinson's disease: Implications for pathogenesis and therapy,” PNAS, 97(2):571-576 (2000).
Jobling and Holmes, “Analysis of structure and function of the B subunit of cholera toxin by the use of site-directed mutagenesis,” Molecular Microbiology, 5(7):1755-1767 (1991).
Jorbeck et al., “Artificial Salmonella Vaccines: Salmonella typhimurium O-antigen-Specific Oligosaccharide-Protein Conjugates Elicit Opsonizing Antibodies that Enhance Phagocytosis,” Infection and Immunity, May:497-502 (1981).
Masliah et al., “β-Amyloid peptides enhance α-synuclein accumulation and neuronal deficits in a transgenic mouse model linking Alzheimer's disease and Parkinson's disease,” PNAS, 98(21):12245-12250 (2001).
Munch et al., “Potentional neurotoxic inflammatory response to Aβ vaccination in humans,” (2002) J. Neural Transm., 109:1081-1087.
Munson ed., “Principals of Pharmacology: Basic Concepts & Clinical Applications,” (1995), 47-48, Chapman & Hall, New York, New York.
Mutschler et al., “Drug Actions: Basic Principles and Therapeutic Aspects,” (1995) 7, 11-12, medpharm Scientific Publishers, Stuttgart, Germany.
Perutz et al., “Amyloid fibers are water-filled nanotubes,” PNAS, 99(8):5591-5595 (2002).
Skolnick and Fetrow, “From genes to protein structure and function: novel applications of computational approaches in the genomic era,” Trends in Biotech, 18(1):34-39 (2000).
Stein and Johnson, “Lack of Neurodegeneration in Transgenic Mice Overexpressing Mutant Amyloid Precursor Protein is Associated with Increased Levels of Transthyretin and Activation of Cell Survival Pathways,” The Journal of Neuroscience, 22(17):7380-7388 (Sep. 1, 2002).
Tennent et al., “Serum amyloid P component prevents proteolysis of the amyloid fibrils of Alzheimer's disease and systemic amyloidosis,” PNAS, 92:4299-4303 (1995).
* cited by examiner

Patent Family

The current document is not in a family.